Social Media Ideas for Galzus Research

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-...

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third...

Glaucoma UK Impact Report 2025

Type of impact: Knowledge creation (publications); tools and methods (biorepository, tool kits); dissemination (engagement activities); collaborations; supporting researchers (earl...

Samsung and Massachusetts General Hospital Launch Joint Study To Investigate GLP-1 Treatment Monitoring With Galaxy Watc...

Samsung Electronics and Massachusetts General Hospital (MGH) Diabetes Research Center (DRC) today jointly announced a research study to investigate the efficacy of Galaxy Watch in...

Optimizing Glutamatergic Neurons for Disease Research

In a groundbreaking advance that promises to reshape the landscape of neurological disease research, a team of scientists has successfully developed an electrophysiological and pro...

Sourced Peptides GLP-3R Review 2026: The 99.745% Purity Listing, Same-Price Vials, and BOGO Offer Putting it on Research...

With three vial sizes listed at the same price and a lot-specific COA displayed by the brand, this Sourced Peptides GLP-3R review examines why the research-use-only compound may st...

Scientists screened thousands of molecules to develop Hympavzi

Researchers spent years searching for a new treatment option for people with hemophilia A or B before arriving at the therapy that became Hympavzi (marstacimab). Scientists at Pfiz...

NewBioRx Highlights Quality Standards Behind Research-Grade GHK-Cu, the Copper Tripeptide With Five Decades of Scientifi...

<![CDATA[Zepzelca Fails to Meet Main Goal of ‌Phase III Lagoon Trial in Second-Line Small Cell Lung Cancer]]>

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted i...

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

<![CDATA[AlzeCure Enters $1 Billion Collaboration and Out-Licensing Agreement with Eli Lilly ]]>

Argenx

Argenx Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Nuritas and Professor Graeme Close Launch Clinical Study Evaluating Bioactive Peptides in Longevity and Healthy...

New landmark research collaboration between Liverpool John Moores University and Nuritas investigates the role of PeptiStrong® in supporting functional strength, muscle health and...

Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal

Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks.

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies drivi...

Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's dis...

Targeted Therapy Advances in H3K27-Altered Glioma

In an era where cancer research continually pushes the boundaries of personalized medicine, a groundbreaking study has emerged, promising newfound hope for patients suffering from...

<![CDATA[The Future for Disease Modifying Therapies for Lysosomal Disorders]]>

Argenx

Argenx Anonymous (not verified) Sat, 05/30/2026 - 14:41 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

<![CDATA[AlzeCure Pharma Enters $2.2 Billion Licensing and Collaboration Agreement with QuantumCell ApS]]>

GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer P...

SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) di...

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (I...

<![CDATA[Ascidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editors]]>

British Heart Foundation - ROMA:Women

Published: July 2026 Summary  The Global Cardiovascular Research Funders Forum (GCRFF) Multinational Clinical Trials Initiative, led by the British Heart Founda...